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Dietary Sargassum fusiforme 
improves memory and reduces 
amyloid plaque load in an 
Alzheimer’s disease mouse model
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Activation of liver X receptors (LXRs) by synthetic agonists was found to improve cognition in 
Alzheimer’s disease (AD) mice. However, these LXR agonists induce hypertriglyceridemia and hepatic 
steatosis, hampering their use in the clinic. We hypothesized that phytosterols as LXR agonists enhance 
cognition in AD without affecting plasma and hepatic triglycerides. Phytosterols previously reported 
to activate LXRs were tested in a luciferase-based LXR reporter assay. Using this assay, we found that 
phytosterols commonly present in a Western type diet in physiological concentrations do not activate 
LXRs. However, a lipid extract of the 24(S)-Saringosterol-containing seaweed Sargassum fusiforme 
did potently activate LXRβ. Dietary supplementation of crude Sargassum fusiforme or a Sargassum 
fusiforme-derived lipid extract to AD mice significantly improved short-term memory and reduced 
hippocampal Aβ plaque load by 81%. Notably, none of the side effects typically induced by full synthetic 
LXR agonists were observed. In contrast, administration of the synthetic LXRα activator, AZ876, did 
not improve cognition and resulted in the accumulation of lipid droplets in the liver. Administration 
of Sargassum fusiforme-derived 24(S)-Saringosterol to cultured neurons reduced the secretion of 
Aβ42. Moreover, conditioned medium from 24(S)-Saringosterol-treated astrocytes added to microglia 
increased phagocytosis of Aβ. our data show that Sargassum fusiforme improves cognition and 
alleviates AD pathology. This may be explained at least partly by 24(S)-Saringosterol-mediated LXRβ 
activation.
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Alzheimer’s disease (AD) is a progressive neurological disorder characterized by an accumulation of extracellular 
amyloid-β (Aβ), intracellular neurofibrillary tangles, loss of synapses, neuroinflammation, and by a gradual pro-
gression of memory loss1. Accumulating evidence suggests a role for a disturbed cholesterol turnover in the cen-
tral nervous system (CNS) in AD pathogenesis2–11. In line with this, stimulation of cholesterol turnover improves 
disease outcome in animal models of AD2,12–18. Liver X receptors (LXR) are master regulators of cholesterol and 
triglyceride turnover and suppress an inflammatory transcriptional profile via trans-repression of NFκB signa-
ling19. Therefore, LXRs are promising well-studied therapeutic targets for increasing cholesterol turnover and 
decreasing neuroinflammation in AD20–24. We and others have reported that synthetic pan LXR agonists improve 
the cognitive phenotype in animal models of AD, decrease synaptic compensatory mechanisms, and stimulate 
the proteolytic degradation of Aβ by microglia2,13,14,24–26. However, synthetic full LXR agonists systematically 
cause adverse side effects, such as hypertriglyceridemia and hepatic steatosis, hampering their translation to the 
clinic27–30.
Phytosterols are structurally similar to cholesterol. However, in contrast to cholesterol, they can cross the 
blood-brain barrier (BBB) and accumulate in brain parenchyma11,31–33. Several of the more than 260 identified 
phytosterols, such as β-sitosterol, fucosterol, stigmasterol, schottenol, 24(S)-Saringosterol, and spinasterol, have 
been reported to activate LXRs in vitro34–39. Moreover, β-sitosterol and stigmasterol modulate AD pathology in 
in vitro models for AD40–42. Phytosterols do not induce hypertriglyceridemia and hepatic steatosis, which may be 
a consequence of their ABCG5/G8-mediated hepatic excretion into the bile11,43,44. The absence of unwanted side 
effects renders phytosterols interesting therapeutic candidates for inducing LXR activation in the CNS.
We aim to identify phytosterols and phytosterol-containing extracts that activate LXRs in vitro, to test their 
effect on memory performance and Aβ plaque pathology in an animal model of AD. We found that phytos-
terols typically present in a Western type diet or extracts from a range of Eastern plants hardly activate LXRα 
Figure 1. A crude lipid extract of Sargassum fusiforme activates LXRβ. LXRα (a) and LXRβ (b) activation was 
assessed with a luciferase-based reporter assay. CHME3 cells were stimulated for 18 hours with vehicle (striped 
bar/dotted line), 1, 3, or 5 µg/μl Sargassum fusiforme or 1, 10 or 100 µg/μl of the specified plant extracts. No 
difference was found between groups (LXRα χ2(7) = 11.55, p = 0.1165, LXRβ χ2(7) = 7.689, p = 0.3608; all 
datasets analysed using Kruskal-Wallis test). All results are displayed as fold change compared to vehicle control 
(striped bar/dotted line). Bars represent mean ± SEM (n ≥ 3).
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or LXRβ. In contrast, a lipid extract of the edible brown seaweed Sargassum fusiforme which contains large 
amounts of 24(S)-Saringosterol potently activated LXRβ. In a mouse model for AD, dietary supplementation 
with Sargassum fusiforme or its lipid extract not only increased the expression of LXR response genes in the CNS, 
but also improved cognition without inducing hepatic steatosis. Improved memory performance in these mice 
was paralleled by a strong reduction in CNS Aβ plaque load. In contrast, the selective LXRα agonist AZ876 did 
not counteract cognitive decline in AD mice or reduce Aβ plaque load, and induced liver steatosis. These findings 
indicate that Sargassum fusiforme is an attractive option for add-on treatments in the emerging field of nutritional 
neuroscience.
Results
phytosterols present in a Western diet do not activate LXRs. First, we determined the capacity of 
phytosterols typically present in a Western diet to activate LXRs. To define cellular specificity in LXR activation in 
vitro, cells derived from peripheral tissues (HEK293.T and COS7) and the CNS (CHME3, MO3.13, N2a/APPswe) 
were tested. Physiologically relevant concentrations of stigmasterol, fucosterol, brassicasterol, β-sitosterol, or a 
mix of phytosterols did not activate LXRα or LXRβ in any of the cell lines used (Fig. S2). An increased incubation 
period promoted the capacity of the synthetic LXR agonist T0901317, but not of phytosterols, to activate LXRα 
and LXRβ (Fig. S3a,b). Although cellular uptake of phytosterols and their capacity to activate nuclear receptors 
improves when complexed to proteins45,46, pre-incubation of phytosterols with BSA did not significantly increase 
their ability to activate LXRα and LXRβ (Fig. S3c,d).
An extract of Sargassum fusiforme activates LXRβ in vitro. In addition to phytosterols present in 
a Western diet, crude extracts of Eastern plants were screened for their capacity to activate LXRα or LXRβ. 
Plants were chosen based on their application in Asian traditional medicine and their presence in an Eastern diet. 
Extracts from Asparagus racemosus, Azadirachta indica, Cassia fistula, Curcuma aromatica, Datura metel, Piper 
retrofractum, Senna tora, and Terminalia chebula did not significantly activate either LXRα or LXRβ in microglial 
CHME3 cells (Fig. 1). However, at a dose of 5 µg/ml an extract of Sargassum fusiforme containing the recently 
identified LXRβ agonist 24(S)-Saringosterol34 significantly activated LXRβ but not LXRα (Fig. 1). Higher doses of 
Sargassum fusiforme induced cell death (data not shown). As Sargassum fusiforme showed the highest capacity to 
activate LXRβ, it was selected for further in vivo testing.
Dietary supplementation with Sargassum fusiforme results in 24(S)-Saringosterol accumula-
tion in the cerebellum and activation of LXR-response genes in AD mice. To assess in vivo effects 
Figure 2. Dietary supplementation with Sargassum fusiforme activates LXRs in the brain. Gene expression 
of Abcg1 (a), Scd1 (b), Srebp-1c (c), Abca1 (d), and ApoE (e) was measured in the brain of WT and 
APPswePS1ΔE9 mice (AD) fed normal chow or chow supplemented with Sargassum fusiforme. Two-way 
ANOVA revealed a diet effect for Abcg1 (F (1, 17) = 6.244, p = 0.0230)), and Scd1 (F (1, 15) = 7.673, p = 0.0143), 
and a genotype effect for Srebp-1c (F (1, 16) = 8.446, p = 0.0103). Gene expression was normalized to Cyca and 
Hmbs, and expressed as fold change compared to WT mice fed the control diet. Bars represent mean ± SEM 
(n ≥ 5).
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Figure 3. Dietary supplementation with Sargassum fusiforme reduces serum cholesterol, and increases 24(S)/
(R)-Saringosterol in serum and cerebellum. Concentrations of 24(S)/(R)-Saringosterol (a,b), cholesterol 
(c,d), cholesterol precursors (e,f), cholesterol metabolites (g,h), and phytosterols (i,j) were determined in 
serum and cerebellum samples of WT and APPswePS1ΔE9 mice (AD) fed either control chow or chow 
supplemented with Sargassum fusiforme. 24(S)/(R)-Saringosterol concentration was affected by diet in CNS 
(F(1, 31) = 438.8, p < 0.0001) and serum (F(1, 31) = 30.05, p < 0.0001) as determined by ANOVA, and 
post-hoc Sidak’s test showed that this effect existed in both genotypes (WT CNS: p < 0.0001; WT serum: 
p = 0.0005; AD CNS: p < 0.0001; AD serum: p = 0.0157). Cholesterol concentration in serum was affected 
by diet (F(3, 31) = 80.59, p < 0.0001) for both genotypes (WT: p < 0.001; AD: p = 0.0002). Regarding the 
cholesterol precursors, concentration of lanosterol was affected by diet in CNS (F(1, 32) = 6.463, p = 0.0161) 
and serum (F(1, 31) = 38.28, p < 0.0001) of WT animals (CNS: p = 0.0265; serum: p = 0.0002) and AD animals 
(serum: p = 0.0024). Concentration of lathosterol was affected by diet in CNS (F(1, 32) = 19.32, p = 0.0001) 
and serum (F(1, 31) = 13.42, p = 0.0009) of WT animals (CNS: p = 0.0076; serum: p = 0.0474). Regarding 
the cholesterol metabolites, concentration of 27-hydroxycholesterol (27OHC) was affected by diet in CNS 
(F(1, 32) = 20.04, p = 0.0009) of WT animals (p = 0.0004). Concentration of 24(S)-hydroxycholesterol (24(S)
OHC) was affected by diet in CNS (F(1, 31) = 8.071, p = 0.0079) of WT animals (p = 0.0079). Regarding the 
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of Sargassum fusiforme APPswePS1ΔE9 mice were used as a model of AD47. These mice begin to develop Aβ 
plaques at 4 months of age and cognitive decline occurs from 6 months onwards48,49. From the age of 5 months 
APPswePS1ΔE9 mice and WT littermates were fed either standard chow or chow supplemented with 50% 
(w/w) dried crude Sargassum fusiforme. Ten weeks of Sargassum fusiforme dietary supplementation resulted in 
LXR activation in the CNS, evidenced by a cerebral induction of LXR response genes (Abcg1, Scd1) (Fig. 2a,b). 
ApoE, Srebp-1c, and Abcg1 expression was not altered in animals treated with Sargassum fusiforme (Fig. 2c–e). 
Interestingly, 24(S)/(R)-Saringosterol was detectable in serum and in the cerebellum of animals that were fed 
Sargassum fusiforme, but not in those fed normal chow (Fig. 3a,b). As Sargassum fusiforme contains predomi-
nantly 24(S)-Saringosterol34, we postulate that this isoforms is the most abundant isoform present in animals fed 
Sargassum fusiforme. Animals fed a diet supplemented with Sargassum fusiforme did not show differences in total 
cholesterol content in the cerebellum (Fig. 3c), but showed a marked reduction in circulating cholesterol levels 
compared to chow fed animals (Fig. 3d). Levels of cholesterol precursors, cholesterol metabolites, and phytoster-
ols were decreased in serum and cerebellum of animals supplemented with Sargassum fusiforme (Fig. 3e–j). On a 
standard chow diet, WT mice displayed significantly higher serum cholesterol levels than AD mice (Fig. 3d), as 
described previously10,50.
Sargassum fusiforme improves memory and reduced Aβ plaque load in AD mice. Next, we inves-
tigated the impact of dietary supplementation with crude Sargassum fusiforme on cognition and neuropathology 
in APPswePS1ΔE9 mice. To assess the influence of selective LXRα activation on cognition, animals were fed 
with the synthetic selective LXRα agonist AZ876. The open field test revealed no effect of genotype or diet on 
general locomotor activity, and anxiety (Table 1). Dietary supplementation with Sargassum fusiforme significantly 
improved object memory in APPswePS1ΔE9 mice in the object recognition task (ORT) at a 1 h but not a 24 h 
inter-trial interval (Fig. 4a,b). In contrast, selective LXRα activation did not impact object memory at either the 
1 h or 24 h inter-trial interval. Sargassum fusiforme, but not AZ786, markedly decreased Aβ plaque load in the 
cortex (70% decrease; Fig. 4c,e) and hippocampus (81% decrease; Fig. 4d,e) in APPswePS1ΔE9 mice. In con-
cordance, Sargassum fusiforme supplementation reduced Aβ40 protein and APP mRNA expression in the CNS 
of AD animals (Fig. 4f,h). Sargassum fusiforme did not significantly reduce insoluble Aβ42 (Fig. 4g). Reduced 
Aβ plaque load was not associated with an increased expression of phagocytic receptors such as Axl and MerTK 
(Fig. S4a,b)51. Yet, the reduced Aβ plaque load was associated with a reduced TREM2 expression, reflecting the 
expelled need for further Aβ clearance (Fig. S4c).
To determine whether the lipid moiety of Sargassum fusiforme was sufficient to modulate the AD-related 
pathology, a purified lipid extract of Sargassum fusiforme was administered daily by oral gavage to APPswePS1ΔE9 
and WT littermates for 45 days. Working memory was significantly improved in APPswePS1ΔE9 mice, resulting 
in the prevention of the spatial working deficit (Fig. 5a,b). In line with these findings, a significant reduction in 
insoluble Aβ42 was observed in the cortex (99% decrease; Fig. 5c) and hippocampus (57% decrease; Fig. 5d) of the 
treated APPswePS1ΔE9 mice. Notably, treatment with the Sargassum fusiforme lipid extract resulted an increased 
expression of ApoE in the CNS (Fig. 5e–g), which indicates active LXR signaling.
Sargassum fusiforme feeding does not lead to liver steatosis. While synthetic LXR agonists are 
well-known to induce liver steatosis in mice52, Sargassum fusiforme supplementation did not induce liver steatosis 
in APPswePS1ΔE9 mice, as evidenced by the absence of lipid droplets within the liver of these animals (Fig. 6a,b). 
Supplementation with AZ876 resulted in a marked increase in lipid droplets in the liver (Fig. 6a,b). Likewise, 
while AZ876 increased circulating triglyceride levels, Sargassum fusiforme did not impact the level of triglycerides 
(Fig. 6c). Similar findings were observed in WT mice fed chow supplemented with Sargassum fusiforme or AZ876 
(data not shown). Sargassum fusiforme is known to contain relatively high levels of (in)organic arsenic that can 
accumulate in the body53. Although relatively high levels of arsenic were measured in dried Sargassum fusiforme 
(40.4 mg/kg), no arsenic accumulation was detectable in lung tissue of the animals that consumed Sargassum 
fusiforme (Fig. 6d).
24(S)-Saringosterol increases microglial Aβ clearance and reduces neuronal Aβ release. To 
obtain insight into the mechanisms by which Sargassum fusiforme-derived 24(S)-Saringosterol impacts AD patho-
genesis we used well-established in vitro models that mimic AD-related pathological processes. Supplementation 
of astrocytes with 24(S)-Saringosterol resulted in an increased ApoE secretion (Fig. 7a,b). Furthermore, supple-
mentation of microglia with conditioned medium of 24(S)-Saringosterol-treated astrocytes promoted microglial 
clearance of Aβ1−42 (Fig. 7c). 24(S)-Saringosterol did not directly impact the capacity of microglia to internalize 
Aβ1−42. (Fig. 7d). Finally, 24(S)-Saringosterol was found to reduce the release of Aβ42 using neuronal N2a cells 
overexpressing APP (Fig. 7e).
plant sterols, concentration of sitosterol was affected by diet in CNS (F(1, 32) = 30.62, p < 0.0001) and serum 
(F(1, 31) = 96.88, p < 0.0001) of WT animals (CNS: p = 0.0026; serum: p < 0.0001) and AD animals (CNS: 
p = 0.0028; serum: p < 0.0001). Concentration of campesterol was affected by diet in CNS (F(1, 32) = 17.02, 
p = 0.0002) and serum (F(1, 31) = 76.4, p < 0.0001) of WT animals (CNS: p = 0.0175; serum: p < 0.0001) and 
AD animals (serum: p < 0.0001). Concentration of stigmasterol was affected by diet in serum (F(1, 31) = 99.89, 
p < 0.0001) of WT animals (p < 0.0001) and AD animals (p < 0.0001). Bars represent mean ± SEM (n = 5). 
Abbreviations:7aOHC 7a-hydroxycholesterol.
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Discussion
Our data show that dietary supplementation with the brown seaweed Sargassum fusiforme improves cognitive 
function and reduces Aβ load in APPswePS1ΔE9 mice without inducing liver steatosis. Our data further sug-
gest the involvement of the stereospecific oxyphytosterol 24(S)-Saringosterol, a selective LXRβ activator, in the 
observed effects on cognition and Aβ plaque load. Considering that selective LXRα activation did not improve 
cognitive decline or Aβ plaque deposition in APPswePS1ΔE9 mice, our findings suggest that natural and possibly 
also synthetic LXRβ agonists are attractive options for the treatment of neurodegenerative disorders such as AD.
Phytosterols, which can cross the blood-brain barrier, have been reported to activate LXRs without inducing 
hypertriglyceridemia and hepatic steatosis, rendering them potentially suitable candidates for treatment of neu-
rodegenerative disorders11. Yet, in contrast with reported data on LXR activation by phytosterols common in a 
Western diet34–39, we observed very little if any effect of stigmasterol, brassicasterol, β-sitosterol, fucosterol, or a 
commercial mix of phytosterols, on activation of LXRα and LXRβ in vitro. The discrepancy between our data and 
the literature may be explained by differences in the experimental design, such as phytosterol concentration, incu-
bation time, and cell type and assay used to measure LXR activation. For instance, we used a cell-based luciferase 
reporter assay and CNS-derived cell lines, as well as HEK293.T and COS-7 cells, to define LXR activation and 
cellular specificity in LXR activation, while other studies used cell-free assays38. Furthermore, we used phytosterol 
concentrations in a physiological range that can be reached through dietary supplementation (1–25 µM), whereas 
other studies used concentrations far exceeding this physiological range up to 200 µM36. Of note, compared to 
synthetic LXR agonists, the reported ability of phytosterols commonly present in a Western diet to activate LXRs 
is relatively limited34–39. In line with this, no alterations were observed in the expression of LXR-response genes 
in the brain of ABCG5-knockout mice despite high cerebral levels of common phytosterols26. In summary, our 
data indicate that phytosterols present in a Western type diet do not activate LXRs at concentrations that can be 
reached through dietary supplementation11.
Out of the tested extracts of Asian plants, the extract of Sargassum fusiforme most potently activated LXRβ 
in vitro. This is in line with the recently reported LXRβ-activating effects of Sargassum fusiforme-derived 
24(S)-Saringosterol34. In Sargassum fusiforme–fed animals, 24(S)-Saringosterol was detected in the cere-
bellum in concentrations equal to common oxysterols, suggesting a good CNS bioavailability. The amount 
of 24(S)-Saringosterol detected in the CNS was comparable to previously reported concentrations of other 
dietary phytosterols in the CNS26,32,33. With respect to these findings, we found that cerebral expression of 
LXR-response genes was upregulated in animals fed Sargassum fusiforme-enriched chow, further supporting the 
ability of Sargassum fusiforme to activate LXRβ. The route of entry of 24(S)-Saringosterol to the CNS remains 
unclear. Further research is warranted to define the role of ApoE and SR-B1 in facilitating the transport of 
24(S)-Saringosterol into the CNS11,32. Moreover, since 24(S)-Saringosterol is oxydated plant sterol, we hypoth-
esize that 24(S)-Saringosterol can enter the CNS via transcellular diffusion, comparable to other oxidized cho-
lesterol derivatives such as 24(S)-Hydroxycholesterol54. Interestingly, in contrast to 24(S)-Saringosterol, all plant 
sterol concentrations decreased in serum and CNS upon feeding Sargassum fusiforme. It can be hypothesized that 
24(S)-Saringosterol activates intestinal and hepatic Abcg5/g8 transporters and thereby drives the enterohepatic 
secretion of plant sterols, thereby lowering circulating levels of sterols55. The latter hypothesis is in line with the 
strong reduction in circulating cholesterol levels we found in this study.
Our data indicate that the LXRα selective agonist AZ876 does not significantly counteract cognitive decline 
or reduce Aβ plaque load in APPswePS1ΔE9 mice. However, no active LXR signaling was found in the CNS of 
AZ876 treated animals, which suggest poor CNS bioavailability of AZ876 and consequently does not allow us to 
conclude that LXRα activation does not impact AD pathology. On the other hand, while both LXRα and LXRβ 
are expressed in the murine CNS, expression of LXRβ is 15-fold higher compared to LXRα56,57. Hence, the relative 
contribution of LXRα activation upon full-LXR agonist treatment is therefore expected to be limited. The latter 
studies may suggest that the beneficial impact of pan-LXR agonists on cognitive decline in AD models likely relies 
on LXRβ activation.
Synthetic LXR agonists that reduce AD pathology and improve cognitive performance induce hypertriglycer-
idemia and liver steatosis2,13,14,24,25,27–30. Sargassum fusiforme supplementation counteracted cognitive decline of 
APPswePS1ΔE9 transgenic mice without inducing hepatic steatosis. This may be explained by selective hepatic 
LXRβ activation, since animals fed AZ786 (2 mg/kg body weight) displayed a marked increase of liver lipid drop-
lets, indicative of liver steatosis. Alternatively, the presence of other protective compounds present in Sargassum 
fusiforme such as fucosterol may prevent hepatic steatosis11. This is supported by the observation that activation 




TIZ walls and 
corners (s) DM (m) N
WT Control 29.5 ± 7.7 570 ± 7.7 36.1 ± 1.6 12
AD Control 29.4 ± 4.2 569.6 ± 4.3 39.0 ± 1.9 13
WT S. fusiforme 30.9 ± 3.4 564.9 ± 4.3 42.0 ± 1.9 9
AD S. fusiforme 33.5 ± 4.1 564.9 ± 5.2 47.6 ± 2.0 7
WT AZ876 28.3 ± 4.3 569.2 ± 4.9 37.3 ± 2.4 11
AD AZ876 31.7 ± 6.4 567.2 ± 6.4 39.9 ± 2.7 13
Table 1. Genotype and diet do not impact general locomotor activity or anxiety levels. Results of open field test. 
Values are displayed as mean ± SEM. Abbreviations: TIZ, time in zone; DM, distance moved.
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Figure 4. Dietary supplementation with Sargassum fusiforme reduces cognitive decline and Aβ plaque 
load in APPswePS1ΔE9 mice. (a,b) Cognitive functioning was determined using the object recognition 
task. The interval between first and second trial was set at 1 hour (1 h ITI) or 24 hours (24 h ITI). D2 value is 
calculated as the ratio between exploration time spent at the new object and the familiar object in the second 
trial, with d2 value > 0 indicating intact object memory. At 1 h ITI the object memory was found to be intact 
in WT animals on control diet (t(9) = 4.71, p = 0.0011, one sample t-test), in WT animals on Sargassum 
fusiforme-supplemented diet (t(9) = 2.166, p = 0.0585, one sample t-test), and in AD animals on Sargassum 
fusiforme-supplemented diet (t(8) = 2.77, p = 0.0243, one sample t-test). Bars represent mean ± SEM from 
two independent experiments (n ≥ 9 per treatment). (c–e) Aβ plaque load was quantified in cortex (d) and 
hippocampus (e) of APPswePS1ΔE9 mice using immunohistochemistry (n ≥ 5 per treatment). Aβ load is 
calculated as percentage of surface coverage, and was found to be decreased in AD animals fed Sargassum 
fusiforme-enriched chow in cortex (F (3, 24) = 25.79, p < 0.0001, ANOVA; Tukey’s post-hoc for diet effect in 
AD genotype: p = 0.0005) and hippocampus (F (3, 24) = 32.13, p < 0.0001, ANOVA; Tukey’s post-hoc for diet 
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We show that dietary supplementation with crude or lipid extract of Sargassum fusiforme reduces Aβ load in 
AD mice. Our in vitro data indicate that factors released by 24(S)-Saringosterol-treated astrocytes promote micro-
glial clearance of Aβ1–42. Within the brain, astrocytes are the major source of the LXR response gene Apoe. ApoE 
is well-known to increase microglial clearance of Aβ59, possibly via inhibiting cellular uptake of Aβ60. Of interest, 
24(S)-Saringosterol and a lipid extract of Sargassum fusiforme increased ApoE protein expression in astrocytes 
and the CNS respectively, which suggests a role for ApoE in the observed increase in microglial Aβ clearance. In 
addition, we provide evidence that 24(S)-Saringosterol decreases the release of Aβ by neurons in vitro. Together, 
these findings indicate that 24(S)-Saringosterol impacts both the clearance and generation of Aβ42. These findings 
are of particular interest, as beneficial effects of LXR agonists on cognition are not necessarily accompanied by a 
reduced Aβ plaque load14,41. Recently, it has been reported that other constituents of Sargassum fusiforme, such as 
fucosterol, fucoidan, and fucoxantin improve learning and memory deficiencies in pharmacological models for 
cognitive impairment61–63. Although synergism among constituents of Sargassum fusiforme is likely, future studies 
should determine whether 24(S)-Saringosterol is sufficient to improve cognitive performance and AD pathology.
Although relatively high levels of arsenic were measured in extracts of Sargassum fusiforme, no arsenic was 
detectable in lung tissue, which generally represents a major reservoir for this element64. Arsenic present in 
Sargassum fusiforme may therefore be rapidly excreted, degraded or absorbed in low amounts in the intestine.
In summary, our data indicate that phytosterols present in a Western type diet do not activate LXRs at con-
centrations that can be reached through dietary supplementation. However, a crude lipid extract of the edible 
seaweed Sargassum fusiforme did selectively activate LXRβ in vitro. Here, we show for the first time that dietary 
supplementation with Sargassum fusiforme significantly improves memory performance and reduces Aβ plaque 
load in a well-established AD model. The accumulation of the natural LXRβ agonist 24(S)-Saringosterol in the 
CNS suggests its involvement in the neuroprotective impact of Sargassum fusiforme. Collectively, our findings 
point to 24(S)-Saringosterol-containing Sargassum fusiforme as being a novel candidate for dietary supplementa-
tion to prevent or modulate neurodegenerative disorders such as Alzheimer’s disease.
Materials and Methods
preparation of plant extracts. Indigenous Asian plants (Asparagus racemosus, Azadirachta indica, Cassia 
fistula, Curcuma aromatica, Datura metel, Piper retrofractum, Sargassum fusiforme, Senna tora, and Terminalia 
chebula), were selected based on their use in Asian traditional medicine as cognition enhancers. Extracts from 
all plants, with exception of Sargassum fusiforme, were prepared by the maceration method. All plants were dried 
in a hot air oven at 50 °C. The dried samples were finely powdered and soaked in 95% ethanol overnight at room 
temperature and filtered with Whatman filter paper No. 3 (Sigma-Aldrich, Bornem, Belgium). Three consecutive 
filtrates were pooled and evaporated in a vacuum rotary evaporator at 40 °C. The crude lipid fraction of Sargassum 
fusiforme was extracted using an adaptation of the Folch method65. Briefly, Sargassum fusiforme was harvested 
by hand in early spring, washed in sea water, boiled for three hours and dried in a hot air oven. Next, dried 
Sargassum fusiforme (Clearspring Ltd, London, UK) was soaked overnight at room temperature in a 2:1 (v/v) 
chloroform and methanol (both VWR, Leuven, Belgium) mixture. The chloroform/methanol extract was evap-
orated under a N2 stream and the remaining lipid fraction was dissolved in ethanol. Using gas chromatography/
mass spectrometry, 24(S)-Saringosterol content of dried Sargassum fusiforme was determined to be 69.4 ng/mg.
Cell culture. Immortalized human embryonic kidney cells (HEK293.T), human microglia (CHME3; a kind 
gift from prof. dr. M. Tardieu, Universite Paris-Sud, France66), human oligodendrocytes (MO3.13), mouse neu-
roblastoma expressing APPswe (N2a/APPswe; a kind gift from prof. dr. T.W. Kim, Colombia University, USA67), 
and monkey kidney cells (COS7) were used for in vitro experiments. All cell lines were cultured in DMEM 
(Sigma-Aldrich) containing 10% heat-inactivated FCS (Invitrogen, Merelbeke, Belgium) and 100 U penicil-
lin/100 µg streptomycin/ml (Invitrogen), at 37 °C/5% CO2. For phytosterol treatment, cells were incubated for 
18 hours in culture medium without FCS containing the Eastern plants extracts, brassicasterol (Sigma-Aldrich), 
β-sitosterol, (Sigma-Aldrich), fucosterol (Sigma-Aldrich), stigmasterol (analytic confirmed purity of 99,9%), phy-
tosterol mix (containing 60% β-sitosterol, 25% campesterol, and 15% stigmasterol; kindly provided by Ingmar 
Wester Raisio, Finland), T0901317 (Cayman Chemicals, Huissen, the Netherlands), ethanol (VWR), or DMSO 
(Sigma-Aldrich).
Luciferase-based nuclear receptor reporter assay. To determine the ability of plant extracts and 
phytosterols to bind LXRα and LXRβ, a luciferase-based reporter assay was performed using the ONE-GloTM 
Luciferase Assay System kit (Promega, Leiden, the Netherlands), according to manufacturer’s instructions. Cell 
lines were transfected with bacterial plasmid constructs expressing luciferase under control of the promotor region 
of the ligand-binding domain for LXRα or LXRβ68. Cells were grown to 50–60% confluency in 60 mm plates, 
transfected with 1.8 μg of plasmid DNA including 0.2 μg pGAL4hLXRα or pGAL4hLXRβ, 1 μg pG5-TK-GL3, and 
0.6 μg of pCMV-β-galactosidase, using JetPEI (Polyplus-transfection SA, Illkirch, France) as transfection reagent. 
Following treatment, cells were lysed in lysis buffer (25 mM Glycyl-Glycine, 15 mM MgSO4, 4 mM EGTA, and 
1x Triton; all from Sigma). To correct for transfection efficacy, β-galactosidase activity was measured using lysate 
diluted 1:10 in B-gal buffer, consisting of 20% 2-Nitrophenyl β-D-galactopyranoside (ONGP; Sigma) and 80% 
effect in AD genotype: p < 0.0001). Representative IHC staining of all groups is shown (e). (f,g) Sargassum 
fusiforme treated APPswePS1ΔE9 mice show a significant decrease in Aβ40 ((f); U = 6, nctrl = 11, nextract = 5, 
p = 0.0133, Mann-Whitney) but not Aβ42 levels (g). (h) Sargassum fusiforme treated APPswePS1ΔE9 mice show 
a significant decrease in the mRNA expression of APP (U = 0, nctrl = 8, nextract = 4, p = 0.0040, Mann-Whitney).
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(v/v) Buffer Z (0.1 M Na2HPO4, 10 mM KCl, 1 mM MgSO4, and 3.4 µl/ml β-mercaptoethanol; all from Sigma). 
Luminescence and absorbance (410 nM) was measured using the FLUOstar Optima (BMG Labtech, Ortenberg, 
Germany).
Animals and diet. Male APPswePS1ΔE9 mice (Radboud University Medical Center, Nijmegen47) were 
backcrossed with female C57Bl6/J mice (Harlan Netherlands B.V., Horst, The Netherlands) to obtain male 
APPswePS1ΔE9 and wild-type (WT) littermates. Animals were housed in a conventional animal facility at 
Hasselt University. Two series of animal experiments were conducted, the first using dietary supplementation of 
dried Sargassum fusiforme, and the second using gavage of a lipid extract of Sargassum fusiforme. A timeline of 
the animal experiments is depicted in Supplemental Fig. 1.
For the first series, experimental diets consisted of either powdered standard chow (Teklad 2018; Harlan 
Netherlands B.V.) or chow supplemented with 50% (w/w) pulverized dried Sargassum fusiforme (Clearspring 
Ltd, London, UK) or the synthetic LXRα agonist AZ876 (2 mg/kg body weight, kindly provided by AstraZeneca, 
Mölndal, Sweden69). The amount of 24(S)-Saringosterol used was 69.4 ng/mg dried Sargassum fusiforme. Based 
on an estimated intake of 7 g dry food/day, the amount of daily 24(S)-Saringosterol corresponds to 242 µg/
day. Animals were divided into three groups and received either the Sargassum fusiforme containing diet 
(APPswePS1ΔE9 n = 13; C57Bl6/J n = 10), AZ876 containing diet (APPswePS1ΔE9 n = 14; C57Bl6/J n = 13), or 
the control diet (APPswePS1ΔE9 n = 13; C57Bl6/J n = 12) from 5 until 7.5 months of age.
The second batch of animals was divided into two groups and received either the Sargassum fusiforme-derived 
lipid extract (APPswePS1ΔE9 n = 9; C57Bl6/J n = 8), or the vehicle (APPswePS1ΔE9 n = 11; C57Bl6/J n = 12) 
from 6 until 7.5 months of age. Lipids of Sargassum fusiforme were extracted using the Folch-method65. Briefly, 
dried Sargassum fusiforme was pulverized and soaked in a 2:1 (v/v) chloroform:methanol (VWR, Leuven, 
Figure 5. Dietary supplementation with a lipid extract of Sargassum fusiforme reduces cognitive decline and 
Aβ plaque load in APPswePS1ΔE9 mice. (a,b) A Sargassum fusiforme lipid extract was administered by gavage 
to determine the impact of Sargassum fusiforme-derived lipids on working memory in the spatial alteration 
Y maze. All mice showed an intact working memory at baseline ((a), spatial alteration > 50% (chance level); 
WT control p = 0.0002; WT Sargassum fusiforme p = 0.0008; AD control p < 0.0001, AD Sargassum fusiforme 
p = 0.0006, one-sample t-test). Upon six weeks of daily treatment (b), the untreated AD group displayed an 
impaired working memory (p = 0.085) while wild type mice and Sargassum fusiforme extract-treated mice 
retained their working memory (WT control p < 0.0001, WT Sargassum fusiforme p = 0.0018, AD Sargassum 
fusiforme p = 0.0008, one-sample t-test). (c,d) The extract-treated APPswePS1ΔE9 mice show a significant 
decrease in formic acid-extracted insoluble Aβ42 levels in the cortex ((c); U = 0, nctrl = 8, nextract = 8, p = 0.0045, 
Mann-Whitney) and in the hippocampus ((d); U = 3; nctrl = 7, nextract = 5, p = 0.0177, Mann-Whitney). (e–g) 
Mice treated with a lipid extract of Sargassum fusiforme show an increased mRNA (e) expression of ApoE in 
their CNS (F (1, 18) = 4.885, p = 0.0403, two-way ANOVA), although the increase in protein expression (f,g) 
does not reach significance. Data are shown as mean ± SEM.
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Belgium) mixture for 16 hours at room temperature. Next, the mixture was sonicated (10 min), filtered, and 
subsequently evaporated by heating the extract until 60 °C. The remaining extract was washed in ethanol, son-
icated (10 min), and evaporated. Finally, the extract was dissolved in corn oil (Vita D’or, the Netherlands) as 
vehicle and sonicated prior to in vivo supplementation. Using gas chromatography/mass spectrometry, 24(S)/
(R)-Saringosterol content was measured to be 332 mg/dl (7,744 mM). The extract was administered by daily gav-
age (200 µl/25 g body weight) for a period of 45 days, corresponding to a daily lipid intake of 3.5 g seaweed/day 
(664 µg 24(S)/(R)-Saringosterol/day). In a previous study we defined that Sargassum fusiforme contains predom-
inantly 24(S)-Saringosterol34. Hence, we expect that this isoforms is the most abundant isoform present in our 
in vivo experiments.
One week prior to the start of the behavioral experiments all animals were housed individually. Animals were 
kept at an inverse 12 h light/12 h dark cycle, and behavioral experiments were performed during the dark phase 
of the cycle. Cognitive performance was scored blind. All animal procedures were performed in accordance with 
institutional guidelines and approved by the ethical committee for animal experiments of Hasselt University.
Behavioral tasks. The object recognition task (ORT) was conducted after 9 weeks of Sargassum fusiforme 
supplementation when the mice were ~8 months old, as described previously70,71. In brief, all animals were habit-
uated to the arena over 2 days, in one trial of 4 min per day. In each habituation trial, two different objects were 
placed symmetrically in the center of the arena, about 10 cm from the wall. Four different objects were available 
and at the end of the habituation period each animal had encountered all four objects once. After one resting 
day, the experiment started. During the first trial (T1) two identical objects (samples) were placed in the arena. 
After exploring the samples for 4 min, the animal was placed back in its home cage. Subsequently, after a pre-
determined delay interval (1 or 24 hours), the second trial of 4 minutes (T2) was performed using one familiar 
object from trial 1 and one new object. Exploration time for each object during T1 and T2 was recorded manually 
using a personal computer. Sitting on the object or biting in the object was not considered exploratory behavior. 
Discrimination index d2 in T2 (d2 = [(exploration time for the novel object) − (exploration time for the familiar 
object)]/(total exploration time in T2)) was calculated as measure for object memory.
The Y-maze spontaneous alternation test72 was conducted at baseline and after 6 weeks of extract treatment. 
The maze used for the Y-maze spatial alteration task consisted of three arms of grey Perspec of equal length 
(40 × 10 × 15 cm) (labeled A, B and C), separated at an angle of 120°. The animals were free to explore the maze 
for 6 minutes. Afterwards, the working memory is calculated in order of percentage of alternations defined as: 
(number of triads/(total number of entries −2)) * 100. The number of triads was recorded manually and was 
defined as subsequently entering the three different arms, while entering an arm was defined as placing both hind 
paws in that arm. After each trial, the maze was cleaned with 70% ethanol to prevent olfactory cues.
Figure 6. Sargassum fusiforme supplementation does not result in liver steatosis, elevated circulating 
triglyceride levels, or arsenic accumulation in the lungs. (a) An ORO staining was performed to define lipid 
droplets in liver samples of APPswePS1ΔE9 mice fed normal chow or Sargassum fusiforme/AZ876-enriched 
chow. (b) Quantification of the ORO staining shown in (1) calculated as number of lipid droplets per mm2 
of liver tissue. (c) AZ876 but not Sargassum fusiforme increases the circulating levels of triglycerides in and 
APPswePS1ΔE9 mice (F (2, 31) = 4.056, p = 0.0272, ANOVA; Tukey’s post-hoc for diet effect: p = 0.0305). (d) 
Arsenic was assesed in dried Sargassum fusiforme and lung samples of WT and APPswePS1ΔE9 mice (AD) fed 
normal chow or chow supplemented with Sargassum fusiforme.
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The open field test (OF) was conducted as described previously73, after 9.5 weeks of Sargassum fusiforme 
treatment. In short, animals were placed in a square, Perspex box (50 cm × 50 cm × 30 cm), with an open top, grey 
walls, and a white floor. Video tracking with a computerized system (Etho VisionTM, Noldus, Wageningen, The 
Netherlands) was used to record and analyse movements and position of the animals, in order to determine time 
in zone (TIZ) and distance moved (DM) over the 10-minute trial14.
tissue sample preparation. Mice were anaesthetized with Nembutal (100 mg/kg i.p., CEVA Logistics, 
Brussels, Belgium) prior to transcardial perfusion with Ringer’s solution. Blood was collected and centrifuged 
for 10 min at 200 g to obtain serum, which was snap-frozen in liquid nitrogen. Liver samples were divided into 
two parts and either directly snap-frozen or frozen in Tissue-Tek O.C.T embedding compound (Sakura Finetek, 
Berchem, Belgium). Brains were divided into three parts prior to snap-freezing; the cerebellum and two hem-
ispheres. The right hemisphere was preserved for immunohistochemistry and frozen in Tissue-Tek O.C.T. 
embedding compound. The rostral half of the left hemisphere was preserved for mRNA expression analyses with 
quantitative PCR. The cerebellum was preserved for sterol analyses.
Aβ quantification. The right hemisphere of the crude Sargassum fusiforme-treated mice was cut in the coronal 
plane with a Leica CM1900UV cryostat (Leica Microsystems, Wetzlar, Germany) to obtain 10 μm sections. Sections 
were mounted on glass slides, air-dried overnight, and stored at room temperature until used. After blocking of 
endogenous peroxidases by incubation for 30 min with 3% H2O2 in methanol, the sections were incubated for 
30 min with blocking solution (5% bovine serum albumin in 1x TBS) followed by overnight 4 °C primary antibody 
incubation in blocking solution (clone 3D6, Amyloid-β Antibody 1:8000). The sections were then incubated in 
Figure 7. 24(S)-Saringosterol increases astrocytic ApoE production and microglial Aβ clearance and reduces 
neuronal Aβ release in vitro. (a,b) Primary astrocytes were treated with 10 µM 24(S)-Saringosterol for 2 
consecutive days and medium was collected 48 h after the last treatment. Western Blot was used to measure 
secreted ApoE in the cellular supernatant. 24(S)-Saringosterol increased ApoE secretion (t(5) = 2.531, 
p = 0.0524, unpaired t-test). Representative WB bands are displayed in the figure. (c) Primary murine microglia 
were examined for their capacity to internalize FAM-labeled Aβ1−42. Microglia were incubated for 1 h with 
fluorescently-labeled FAM-Aβ1−42 and 40% conditioned medium derived from astrocytes treated with vehicle 
(ethanol) or 24(S)-Saringosterol (10 µM). Data are depicted as the percentage of cells that phagocytosed 
FAM-Aβ1−42. 24(S)-Saringosterol increased microglial uptake of FAM-Aβ1−42 (t(14) = 2.218, p = 0.0436, 
unpaired t-test). (d) To define a direct effect on microglial uptake of Aβ1−42, primary murine microglia were 
exposed to 24(S)-Saringosterol prior to defining FAM-labeled Aβ1−42 uptake. (e) N2aAPPswe cells were 
stimulated with vehicle (ethanol) or 24(S)-Saringosterol (10 µM). ELISA was used to define the release of Aβ42. 
24(S)-Saringosterol decreased Aβ42 production (t(5) = 8.126, p = 0.0005, unpaired t-test).
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biotinylated goat anti-human IgG (BA-3000, 1:1000, Vector Laboratories, Burlingame, CA), and the immunore-
activity was developed by the ABC avidin–biotin peroxidase KIT (PK-6100, Vector) for 1 hour, and 5 min with 
diaminobenzidine (DAB, ImmPACT SK-4105, Vector). Between every other step, the slides were rinsed (3×) with 
TBS/0.3% Triton-X 100. The sections were counterstained with haematoxylin for 30 seconds and coverslipped. 
Digital images of the sections were obtained using a Leica DM 2000 LED microscope (Leica Microsystems, Diegem, 
Belgium) equipped with hardware and software from Leica Application suite software (Leica Microsystems). The 
Aβ plaque load was quantified in 3 sections per brain in 5 animals per group using Fiji ImageJ, by defining the pixel 
intensity of Aβ plaques in the total cortical or hippocampal area at Bregma −1.5 to −2.5.
Next, left hippocampus and cortex were dissected from the brains of the Sargassum fusiforme extract-treated 
APPswePS1ΔE9 mice and homogenated in a 2% SDS TBS-T buffer. Aβ42 levels were quantified and related to 
the protein content in the starting homogenate using an Aβ42 ELISA (Invitrogen, USA), according to the manu-
facturer’s instructions74. In brief, the homogenates were sonicated twice and mixture centrifuged to generate an 
SDS-insoluble fraction (21000 g, 10 min). The SDS-insoluble pellet was sonicated twice in 70% formic acid (FA), 
yielding the FA-extracted insoluble Aβ42 fraction.
Mouse neuroblastoma (N2a) cells, stably overexpressing APP, were cultured in high glucose DMEM medium 
supplemented with 10%FCS and 100 U pen/100 µg strep/ml (37 °C, 5% CO2) Next, the cells were incubated for 
24 h with ethanol (vehicle control) or 10 µM 24(S)-Saringosterol, purified from Sargassum fusiforme as described 
earlier34. Aβ42 levels were detected in supernatant using an Aβ42 ELISA (Invitrogen, USA), according to the man-
ufacturer’s instructions.
Determination of astrocytic Apoe secretion. To generate 24(S)-Saringosterol-astrocyte conditioned 
medium, mouse primary astrocytes were seeded in a 24-well plate with a density of 250000 cells/well. Next, astro-
cytes were treated with either 10 µM purified 24(S)-Saringosterol or ethanol for 2 consecutive days after which 
medium was replenished and collected 2 days afterwards. Next, ApoE secretion was determined using western 
blot. Equal amounts of cellular supernatant (40 µl) were loaded and separated via electrophoresis through a 10% 
sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE). Afterwards, proteins were transferred onto a PVDF 
membrane (VWR, Belgium), and blots were blocked (5% non-fat dry milk TBS-Tween solution) for 1 h at room 
temperature. Next, membranes were incubated with rabbit anti-ApoE primary antibody (ABBIOTEC, USA). 
After washing the membranes with TBS-Tween, the blots were incubated with swine anti-rabbit HRP conju-
gated antibody (WAKO, Japan). Finally, membranes were washed in TBS and protein bands were detected using 
PierceTM ECL Plus Western Blotting Substrated and ImageQuantTM LAS 4000 mini. ImageJ (http://imagej.nih.
gov/ij/) was used to quantify the protein bands.
Aβ phagocytosis assay. Primary murine cells were isolated and cultured as described previously75. In 
short, mixed glial cultures were prepared from postnatal d0 mouse cerebral cortices of C57Bl6/J mice (Harlan 
Netherlands B.V.) and cultured in high glucose DMEM medium supplemented with 10% FCS and 100 U 
pen/100 µg strep/ml. Mixed glial cultures were used to generate microglia-enriched glial cultures by separating 
the microglia from the astrocyte monolayer using orbital shaking followed by purification via differential adhe-
sion to plastic after 14 days in culture. Purified microglia were seeded on poly-L-lysine (5 µg/ml; Sigma-Aldrich) 
coated 96-well plates with a density of 50000 cells/well. Primary microglia were cultured in high glucose DMEM 
medium supplemented with 10% FCS, 100 U pen/100 µg strep/ml and 15% L929 conditioned medium.
Gene symbol Gene name Forward and reverse primer
Cyca Cyclin-A F: TGGGATTGTACCACAGCTCCAR: CTCATGATGACTGCAGCAAACC
Hmbs Hydroxymethylbilane synthase F: GATGAAGCCATTGCTGAACTTGR: GTCTCCTTGGGTATCCGATGTC
Abca1 ATP-binding cassette, sub-family A, member 1 F: CCCAGAGCAAAAAGCGACTCR: GGTCATCATCACTTTGGTCCTTG
Abcg1 ATP-binding cassette, sub-family G, member 1 F: CAAGACCCTTTTGAAAGGGATCTR: GCCAGAATATTCATGAGTGTGGAC
ApoE Apolipoprotein E F: CCTGAACCGCTTCTGGGATTR: GCTCTTCCTGGACCTGGTCA
App Amyloid precursor protein F: CGA ACC CTA CGA AGA AGC CACR: GCT TTC TGG AAA TGG GCA TGT TC
Axl Axl receptor tyrosine kinase F: GGA ACC CAG GGA ATA TCA CAG GR: AGT TCT AGG ATC TGT CCA TCT CG
Mertk Proto-oncogene tyrosine-protein kinase Mer F: TGC GTT TAA TCA CAC CAT TGG AR: TGC CCC GAG CAA TTC CTT TC
Scd1 Stearoyl-CoA desaturase 1 F: TGCGATACACTCTGGTGCTCAR: CTCAGAAGCCCAAAGCTCAGC
Srebp-1c Sterol regulatory element binding protein 1c F: GGAGCCATGGATTGCACATTR: GCTTCCAGAGAGGAGCCCAG
Trem2 Triggering receptor expressed on myeloid cells 2 F: CTG GAA CCG TCA CCA TCA CTCR: CGA AAC TCG ATG ACT CCT CGG
Table 2. Quantitative PCR primers. Nucleotide sequence of primers used for quantitative PCR. F denotes 
forward primer, R denotes reverse primer.
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The capacity of primary microglia to phagocytose FAM-labeled Aβ1−42 (Eurogentec, Seraing Belgium) 
was assessed with a plate-based assay. Twenty hours after seeding the microglia, cells were treated with 
24(S)-Saringosterol-astrocyte conditioned medium (40%) and FAM-labeled Aβ1−42 was added for 1 h at a final 
concentration of 500 nM. Next, medium was removed and 100 µl 0.2% trypan blue in PBS (pH 4.4) was added to 
quench extracellular Aβ. After aspiration, fluorescence was measured at 485/535 nm excitation/emission. Finally, 
to normalize for cell number, 100 µl DAPI in PBS was added, incubated for 10 min and medium was aspirated. 
Fluorescence was subsequently measured in a plate reader using 360 nm/465 nm excitation/emission wavelengths.
Sterol profile and triglyceride content determination. Sterol profiles were determined in serum and 
cerebellum. Preceding the analysis, samples were spun in a speed vacuum dryer (Savant AES 1000) at 12 mbar for 
24 h to relate individual sterol concentrations to their dry weight. The sterols were extracted from the dried tissue 
by placing them in a mixture of chloroform:methanol (2:1) for 24 h at 4 °C. Sterol levels were determined by gas 
chromatography/mass spectrometry (GC/MS) as described previously32,76. Triglyceride contents of serum were 
determined using the GOD-PAP method with enzymatic reagent kits according to manufacturer’s instructions 
(DiaSys Diagnostic Systems, Holzheim, Germany).
Determination of arsenic concentration. Arsenic halogenide concentrations in lung tissues were ana-
lyzed using inductively coupled plasma-optical emission spectrometry (ICP–OES, Agilent Technologies, 700 
Series, Belgium). Tissues were oven-dried and digested with 70–71% HNO3 in a heat block. Prior to analysis, lung 
samples and dried Sargassum fusiforme were diluted 1:10 in 1% nitric acid. Concentrations were measured using 
a standard calibration curve (NIST Spinach 1570a).
RNA isolation and Rt-Q-pCR. Brain tissue was homogenized in Qiazol (Qiagen, Venlo, The Netherlands) 
preceding RNA isolation, and total RNA was prepared using the RNeasy mini kit (Qiagen), according to man-
ufacturer’s instructions. RNA concentration and quality was determined with a NanoDrop spectrophotometer 
(Isogen Life Science, IJsselstein, The Netherlands). RNA was reverse transcribed to cDNA using the qScriptTM 
cDNA synthesis kit (Quanta Biosciences, Gaithersburg, USA). As previously described77,78, quantitative PCR was 
subsequently conducted on a StepOnePlus detection system (Applied biosystems, Gaasbeek, Belgium). Relative 
quantification of gene expression was performed using the comparative Ct method. Data were normalized to the 
most stable reference genes (Cyca and Hmbs). Primers were chosen according to literature or designed using 
Primer-Express (http://www.ncbi.nlm.nih.gov/tools/primer-blast), and details of primers used are shown in 
Table 2.
experimental design and statistical analyses. All statistical analyses were performed using GraphPad 
Prism 7TM and are reported as mean ± SEM. D’Agostino and Pearson omnibus normality test was used to test 
normal distribution. Unless specified differently, one-way ANOVA (post-hoc: Tukey) or two-tailed unpaired 
Student t-test was used for normally distributed data sets. The Kruskal-Wallis (Dunns post hoc comparison) or 
Mann–Whitney analysis was used for data sets assessed not to be normally distributed. The ORT discrimination 
index d2 (compared to the 0) and spatial alteration Y-maze performance (compared to the 50% chance level) was 
analyzed using the one-sample t-test. Animals that did not reach the minimum of 4 s exploration in T1 or T2 were 
excluded from further analysis71,79. Data from RT-Q-PCR was analyzed using two-way ANOVA with treatment 
and genotype as independent variables. In all data sets, extreme values were excluded by means of Dixon’s princi-
ples of exclusion of extreme values80,81. Significance levels are denoted as follows: $p < 0.10 *p < 0.05, **p < 0.01, 
***p < 0.001 or ****p < 0.0001.
ethical approval. All animal procedures were performed in accordance with institutional guidelines and 
approved by the ethical committee for animal experiments of Hasselt University.
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on rea-
sonable request.
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